By Peter Devenny
A new site for the production of gastroenterology and anti-inflammatory medicines via an oral solid dose tablets and capsules form for the local
Indian market is due to be in production in Q1 2018. Eight billion tablets and one billion capsules are expected to be produced at full production capacity in any one-year period.
The manufacture of gastroenterology and antiinflammatory medicines gives challenges in the operations process in the form of ensuring occupational safety is maintained to allowable levels. Health and safety data for each product involved in the manufacturing process was reviewed and evaluated by Extract Technology and the client to determine that the correct containment solution was implemented. Potent active ingredients used in the process pose the highest risk to operator safety.